Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prelude TherapeuticsPRLD -2.93%30 Price-to-Tangible-Book is 3.15 as of Sep. 08, 2026. GuruFocus rates PRLD with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, Prelude Therapeutics ranks better than 51.2% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Prelude Therapeutics Price-to-Tangible-Book Related Terms
Prelude Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRLD vs CMPX, ARCT, AVIR: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Prelude Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Prelude Therapeutics (PRLD) has a Price-to-Tangible-Book of 3.15 as of Sep. 08, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Prelude Therapeutics and its competitors. According to the industry distribution chart, Prelude Therapeutics ranks #550 out of 1127 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Prelude Therapeutics' Price-to-Tangible-Book too high?
Prelude Therapeutics' current Price-to-Tangible-Book is 3.15. The Biotechnology industry median Price-to-Tangible-Book is 3.38. Prelude Therapeutics' value of 3.15 is 6.8% below this industry median. Based on the distribution chart, Prelude Therapeutics ranks #550 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Price-to-Tangible-Book compare to CMPX and ARCT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #550 out of 1127 companies for Price-to-Tangible-Book. This puts Prelude Therapeutics in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.38. Prelude Therapeutics' value of 3.15 is 6.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.38, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current Price-to-Tangible-Book of 3.15 is 6.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Prelude Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current Price-to-Tangible-Book is 3.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Price-to-Tangible-Book of 3.15. The current Price-to-Tangible-Book is 3.15 and 6.8% below the Biotechnology industry median of 3.38. Prelude Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Price-to-Tangible-Book is 3.15 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
30GF Score
Get the complete analysis for PRLD
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
